ATRIAL FIBRILLATION: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND MANAGEMENT
Keywords:
atrial fibrillation, cardiac arrhythmia, pathophysiology, clinical manifestations, anticoagulation, rate control, rhythm controlAbstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with significant morbidity and mortality. Its prevalence increases with age and the presence of comorbidities such as hypertension, diabetes mellitus, heart failure, and structural heart disease. AF is characterized by rapid, irregular atrial electrical activity that leads to impaired atrial contraction, hemodynamic compromise, and increased risk of thromboembolic events, particularly stroke. The pathophysiology of AF is complex and involves triggers such as ectopic foci, atrial structural remodeling, and electrophysiological changes that promote reentry circuits. Clinical manifestations range from asymptomatic episodes detected incidentally to symptomatic presentations including palpitations, fatigue, dyspnea, and dizziness. Complications of AF, particularly thromboembolism, significantly affect patient prognosis and quality of life. Management of AF requires a multifaceted approach, including rate or rhythm control strategies, anticoagulation to prevent thromboembolic events, and consideration of invasive procedures such as catheter ablation in selected patients. Early recognition, risk stratification, and individualized treatment plans are essential to optimize outcomes.
This review summarizes current understanding of the epidemiology, pathophysiology, clinical manifestations, and management strategies of atrial fibrillation, emphasizing the importance of early detection and comprehensive care to reduce morbidity and improve patient prognosis.
References
January CT, Wann LS, Calkins H, et al. 2020 ACC/AHA Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2020;142:e125–e467.
Kirchhof P, Benussi S, Kotecha D, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2020;42:373–498.
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847.
Nattel S, Harada M. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ J. 2014;78:1292–1300.
Heijman J, Guichard JB, Dobrev D, Nattel S. Atrial fibrillation pathophysiology: remodeling, triggers, and autonomic modulation. Circ Res. 2014;114:1453–1468.
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747.
January CT, Wann LS. Atrial fibrillation: mechanisms and management. JAMA. 2010;303:2156–2167.
Bunch TJ, Crandall BG, Weiss JP, et al. Atrial fibrillation: pathophysiology and clinical implications. Mayo Clin Proc. 2009;84:422–439.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285:2370–2375.
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Eur Heart J. 2006;27:1979–2030.
Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952.
Nattel S, Harada M, Dobrev D. Atrial fibrillation: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2017;14:30–44.
Zimetbaum P. Atrial fibrillation. Ann Intern Med. 2017;166:ITC33–ITC48.
Kotecha D, Piccini JP. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Heart. 2015;101:1194–1201.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42:373–498.






Azerbaijan
Türkiye
Uzbekistan
Kazakhstan
Turkmenistan
Kyrgyzstan
Republic of Korea
Japan
India
United States of America
Kosovo